QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 oppenheimer-reiterates-outperform-on-kala-bio-maintains-15-price-target

Oppenheimer analyst Francois Brisebois reiterates Kala Bio (NASDAQ:KALA) with a Outperform and maintains $15 price target.

 kala-bio-q2-eps-316-beats-440-estimate

Kala Bio (NASDAQ:KALA) reported quarterly losses of $(3.16) per share which beat the analyst consensus estimate of $(4.40) by 2...

 hc-wainwright--co-maintains-buy-on-kala-bio-lowers-price-target-to-18

HC Wainwright & Co. analyst Yi Chen maintains Kala Bio (NASDAQ:KALA) with a Buy and lowers the price target from $21 to ...

 kala-pharmaceuticals-q1-2024-adj-eps-420-misses-289-estimate

Kala Pharmaceuticals (NASDAQ:KALA) reported quarterly losses of $(4.20) per share which missed the analyst consensus estimate o...

 hc-wainwright--co-maintains-buy-on-kala-bio-lowers-price-target-to-21

HC Wainwright & Co. analyst Yi Chen maintains Kala Bio (NASDAQ:KALA) with a Buy and lowers the price target from $22 to ...

 oppenheimer-reiterates-outperform-on-kala-bio-maintains-15-price-target

Oppenheimer analyst Francois Brisebois reiterates Kala Bio (NASDAQ:KALA) with a Outperform and maintains $15 price target.

 hc-wainwright--co-maintains-buy-on-kala-bio-lowers-price-target-to-22

HC Wainwright & Co. analyst Yi Chen maintains Kala Bio (NASDAQ:KALA) with a Buy and lowers the price target from $24 to ...

 kala-bio-q3-earnings-insights
Kala Bio: Q3 Earnings Insights
11/13/2023 13:30:13

 kala-pharmaceuticals-q3-eps-341-misses-215-estimate

Kala Pharmaceuticals (NASDAQ:KALA) reported quarterly losses of $(3.41) per share which missed the analyst consensus estimate o...

 hc-wainwright--co-reiterates-buy-on-kala-bio-maintains-24-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Kala Bio (NASDAQ:KALA) with a Buy and maintains $24 price target.

 kala-pharmaceuticals-q2-eps-436-up-from-1892-yoy-592m-in-cash-cash-equivalents-and-short-term-expected-to-fund-operations-into-2q-2025

Kala Pharmaceuticals (NASDAQ:KALA) reported quarterly losses of $(4.36) per share. This is a 76.96 percent increase over losses...

 kala-pharmaceuticals-announces-name-change-to-kala-bio-effective-august-2-2023

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and...

 10-short-squeeze-stocks-to-watch-aeglea-biotherapeutics-toro-corp-airsculpt-a-company-moves-up-4166-positions--more

Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a focus of new traders looking for th...

 10-short-squeeze-stocks-to-watch-toro-corp-paxmedica-getty-images-and-more

Potential short squeeze plays gained steam in 2021, continued through 2022, and remain a focus of new traders looking for the n...

 hc-wainwright--co-reiterates-buy-on-kala-pharmaceuticals-raises-price-target-to-24

HC Wainwright & Co. analyst Yi Chen reiterates Kala Pharmaceuticals (NASDAQ:KALA) with a Buy and raises the price target...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION